RecruitingPhase 2NCT07552012
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU
Studying Anterior uveitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Intervention
- FXS5626 tablet(other)
- Enrollment
- 40 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2026 – 2027
Study locations (1)
- EC of the First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07552012 on ClinicalTrials.govOther trials for Anterior uveitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07285070Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior UveitisNovaliq GmbH
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07218770A Study of REGN7041 for Active Noninfectious Uveitis in Adult ParticipantsRegeneron Pharmaceuticals
- ACTIVE NOT RECRUITINGNANCT07262437Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine ProfilesUniversity of Milan
- ACTIVE NOT RECRUITINGPHASE3NCT06431373A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior UveitisPriovant Therapeutics, Inc.
- RECRUITINGNCT07065747Quantification & Classification of Inflammatory Cells in Uveitis Using OCTOregon Health and Science University
- RECRUITINGNCT06720376Observational Prospective Turkish Inception Cohort of Uveitis and SpondyloarthritisMarmara University
- RECRUITINGPHASE3NCT05486468The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior SegmentTexas Retina Associates
- RECRUITINGNANCT05286203Ocular Pathogen and Transcriptome Investigation Using Comprehensive SequencingUniversity of California, San Francisco